Donate by 12/31
Home | News | Events | Press | Contact  

About UseNewsletterMessage BoardsAction CenterAdvocateWalk to End Alzheimer’sShopDonate

Find your chapter:

search by state

In My Community
New York University Clinical Trials
Text Size controlsNormal font sizeMedium font sizeLarge font size



Research Opportunities 

Longitudinal Study of Normal Aging, Mild Cognitive Impairment (MCI) and Alzheimer’s Disease 
Participants receive a comprehensive diagnostic evaluation and are reevaluated every year. The goal is to improve early diagnosis and better understand the clinical course and causes of age-related cognitive decline and AD. For information, call Thet Oo at 212-263-8088; mailto:thet.oo@nyumc.org

Early AD Diagnosis 

Clinical Correlates of Longitudinal PET Changes in Alzheimer’s Disease
The goal is to assess combining FDG-PET imaging (brain metabolism) with cerebrospinal fluid (CSF) biomarkers and PET amyloid imaging (using a tracer that binds to brain amyloid) in predicting cognitive decline. We are enrolling mild AD, MCI and normal subjects over age 20 who receive a comprehensive evaluation: neurological/physical exam, MRI and PET, memory testing, laboratory blood-work, EKG and lumbar puncture. Participants receive results and are compensated for their time and effort. For more information, call 212-263-7795; megan.cummings@nyumc.org.

Maternal History of Alzheimer Predisposes Children to Brain Hypometabolism 
The goal is to determine whether young subjects (age 20- 60) with maternal family history of AD show reductions in the brain’s ability to use sugar, and to see if there are greater reductions in subjects with family history spanning 2 generations (i.e., mother and grandmother affected with AD). For more information, contact John Murray at 212-263-7795; john.murray@nyumc.org

Effects of Memantine on Magnetic Resonance Spectroscopy in persons at risk for AD 

This study is for adults 55-90 with memory complaints and a family history of AD, but without any signs of memory decline. We are testing whether Memantine, a drug approved for the treatment of moderate to severe AD, may be beneficial in these at risk individuals. The study duration is 6 months. The brain effects of memantine are measured with magnetic resonance spectroscopy (MRS), a scan to investigate in the chemical substances that make up the brain. For information, call Lidia Glodzik at 212-263-5698; lidia.glodzik@nyumc.org.

Imaging Neuroinflammation in Alzheimer’s Disease with [11C]Arachidonic Acid (AA) and PET
 
The goal is to validate a new inflammation PET imaging agent known as [11C] Arachidonic Acid (AA) in individuals with and without cognitive dysfunction. Inflammation is a key component of the pathological processes (amyloid beta plaque deposition, neurofibrillary tangles, neuronal loss, astrocytosis) that are found in patients with Alzheimer disease (AD). An in vivo neuroimaging method to measure markers of neuroinflammation would represent a major advance in the understanding of the pathophysiology of AD and other dementing disorders. We are enrolling normal and dementia subjects over the age of 65 who receive physical examination, blood tests, neuropsychological evaluation, EKG, MRI; [11C]PIB, [18F]FDG, and [11C] AA PET scans. Participants receive results and are compensated for their time and effort. For information, contact Ricardo Osorio at 212-263-3258; Ricardo.osorio@nyumc.org

MRI Progression Markers of Cognitive Decline in the Elderly 

This project investigates the relationship between plasma amyloid beta protein levels and brain vascular response to CO2 (measured with MRI). Additional tests include brain structure measurement and CSF tau levels. Participants should have mild cognitive impairment (MCI), and will receive a comprehensive evaluation consisting of a neurological/physical examination, neuroimaging (MRI and ASL), memory testing, laboratory blood-work, ECG and lumbar puncture. Participants receive results and are compensated for their time and effort. For information, contact Vanessa Bikhazi at 212- 263-7563; vanessa.bikhazi@nyumc.org.

Biomarkers in Early Alzheimer’s Disease

This project builds upon on our new work demonstrating the value of cerebrospinal fluid (CSF) and blood biomarkers. We combined these analyses with novel MRI technology which looks at cerebral blood flow, a possible mechanism-based marker for early Alzheimer’s disease. We are enrolling normal subjects over the age of age 50, with and without mild memory complaints to receive a comprehensive evaluation: neurological/physical exam, MRI and memory testing, laboratory blood-work, EKG and lumbar puncture. Participants receive results and are compensated for their time and effort. For information, contact Vanessa Bikhazi at 212-263- 7563; vanessa.bikhazi@nyumc.org


 

Alzheimer's Association

Our vision is a world without Alzheimer's
Formed in 1980, the Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.